Skip to content
Home/Companies/Pharma/APONTIS PHARMA

APONTIS PHARMA

Pharma·Germany·Exited 2024·Held 6yr
Entry
2018
Hold
6yr
Exit
2024

Who owns APONTIS PHARMA?

APONTIS PHARMA was owned by Paragon Partners through Paragon Fund II (2014 vintage) from 2018 to 2024, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-07-02

Paragon Partners
Investor
Paragon Partners
Paragon Fund II · 2014 · Buyout

Key facts

HQGermany
SectorPharma
StatusActive
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2024

More from Paragon Fund II

Other portfolio companies in the same fund.

Asic Robotics
Exited 2026
IndustrialsSwitzerland· 2018
to
inprotec
Exited 2022
IndustrialsGermany· 2018
to
UNICEPTA
Unicepta
Exited 2024
Business ServicesGermany· 2018
to
chicco di caffe
Exited 2023
Business ServicesGermany· 2017
to
Condecta
Condecta
Exited 2024
Business ServicesSwitzerland· 2017
to
WEMAS
Wemas
Exited 2023
IndustrialsGermany· 2017
to

More PE-backed in Pharma

Comparable pharma deals from other GPs.

Advantice Health
Advantice Health
Active
TA AssociatesUS
Alvogen
Alvogen
Active
CVC Capital Partners
CANbridge
CANbridge
Active
General AtlanticChina
Ceva
Ceva
Exited 2025
iXO Private EquityFrance
to
curia
curia
Active
The Carlyle GroupUS
Ideal Cures Pvt. Ltd.
Ideal Cures Pvt. Ltd.
Active
TA AssociatesIndia
Track Apontis Pharma

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Apontis Pharma?

6 strategic and 114financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Apontis Pharma.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue